Related Experiment Video
Updated: Oct 18, 2025
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
Published on: October 4, 2022
Determinants of Homologous Recombination Deficiency in Pancreatic Cancer
Max M Wattenberg1,2, Kim A Reiss1,2
1Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract:
Pancreatic cancer is a treatment-resistant malignancy associated with high mortality. However, defective homologous recombination (HR), a DNA repair mechanism required for high-fidelity repair of double-strand DNA breaks, is a therapeutic vulnerability. Consistent with this, a subset of patients with pancreatic cancer show unique tumor responsiveness to HR-dependent DNA damage triggered by certain treatments (platinum chemotherapy and PARP inhibitors). While pathogenic mutations in HR genes are a major driver of this sensitivity, another layer of diverse tumor intrinsic and extrinsic factors regulate the HR deficiency (HRD) phenotype. Defining the mechanisms that drive HRD may guide the development of novel strategies and therapeutics to induce treatment sensitivity in non-HRD tumors. Here, we discuss the complexity underlying HRD in pancreatic cancer and highlight implications for identifying and treating this distinct subset of patients.
Insights
Pancreatic cancer is highly lethal, but defects in homologous recombination (HR) DNA repair offer a therapeutic vulnerability. Understanding HR deficiency (HRD) mechanisms can reveal new treatments for pancreatic cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pancreatic cancer is a deadly disease with limited treatment options.
- Defective homologous recombination (HR) DNA repair is a key vulnerability in some cancers.
- Tumor response to DNA damaging agents like platinum chemotherapy and PARP inhibitors is linked to HR status.
Purpose of the Study:
- To explore the complex mechanisms underlying homologous recombination deficiency (HRD) in pancreatic cancer.
- To identify factors contributing to HRD beyond pathogenic mutations in HR genes.
- To discuss the implications of understanding HRD for developing novel therapeutic strategies.
Main Methods:
- Review of current literature on DNA repair mechanisms in pancreatic cancer.
- Analysis of factors influencing the HRD phenotype in tumors.
- Discussion of therapeutic strategies targeting HRD.
Main Results:
- Homologous recombination deficiency (HRD) presents a therapeutic vulnerability in a subset of pancreatic cancers.
- Both intrinsic tumor factors and extrinsic influences contribute to the HRD phenotype.
- Pathogenic mutations in HR genes are a primary driver of sensitivity to DNA damaging agents.
Conclusions:
- Defining the multifaceted mechanisms of HRD is crucial for improving pancreatic cancer treatment.
- Targeting HRD could enhance sensitivity to existing therapies and inspire new treatment approaches.
- Further research into HRD drivers may unlock strategies to sensitize non-HRD pancreatic tumors to therapy.
Related Concept Videos
02:53Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
02:31Homologous Recombination
01:20Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...